The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for patients with extensive-stage small cell lung cancer.
 
Chul Kim
No Relationships to Disclose
 
Deepa Suresh Subramaniam
Consulting or Advisory Role - AstraZeneca
Research Funding - Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst)
 
Stephen V. Liu
Consulting or Advisory Role - ARIAD; AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; Ignyta; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Bayer; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Ignyta; Lycera; MedImmune; Merck; OncoMed; Pfizer; Threshold Pharmaceuticals
 
Giuseppe Giaccone
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; G1 Therapeutics; Inivata
Research Funding - AstraZeneca; Karyopharm Therapeutics; Lilly